For Physicians



To evaluate a survival benefit for custirsen in combination with second-line docetaxel treatment in approximately 1,100 patients with NSCLC.

Trial Design: 

Randomized, open-label, two-arm trial of custirsen in ~1,100 patients with advanced or metastatic NSCLC who have progressed after initial chemotherapy treatment has failed.

Arm A: 
Custirsen + Docetaxel
Arm B: 
Primary Endpoint: 
Overall survival
Estimated Primary Endpoint Date: 

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue